AHA Scientific Sessions 2026 · TYDAL-TIMI 78
Dirk Blom
General / Preventive / Lipids · University of Cape Town
Good to see the results of this study. It will be very interesting to see how we ultimately manage high triglycerides beyond fibrates and omega-3 supplements once all the data is in. What will be the best target - apoC3, ANGPTL3 or 4? And can we identify groups that benefit more from one therapy than another? For FCS apoC3 inhibition works while evinacumab did not seem to be effective. And will the effects on glycemia (or lack of effect) be an important consideration?
ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels
New England Journal of MedicineMichelle L. O’Donoghue et al.